[18F]FE@SUPPY and [18F]FE@SUPPY:2 - metabolic considerations

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 421-426

  Haeusler, Daniela ^a,b   Nics, Lukas ^a,b   Mien, Leonhard Key ^a,b   Ungersboeck, Johanna ^a,b   Lanzenberger, Rupert R ^a   Shanab, Karem ^b   Sindelar, Karoline M ^a   Viernstein, Helmut ^b   Wagner, Karl Heinz ^b   Dudczak, Robert ^a   Kletter, Kurt ^a   Wadsak, Wolfgang ^a,b   Mitterhauser, Markus ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adenosine A3 receptor; Carboxylesterase; Fluorine 18; Metabolism; PET; SUPPY

Indexed keywords

5 (2 FLUOROETHYL) 2,4 DIETHYL 3 (ETHYLSULFANYLCARBONYL) 6 PHENYLPYRIDINE 5 CARBOXYLIC ACID F 18; 5 ETHYL 2,4 DIETHYL 3 (2 FLUOROETHYLSULFANYLCARBONYL) 6 PHENYLPYRIDINE 5 CARBOXYLIC ACID F 18; ACETONITRILE; ADENOSINE A3 RECEPTOR; CARBOXYLESTERASE; METHANOL; PHOSPHATE BUFFERED SALINE; TRACER; UNCLASSIFIED DRUG; 5 (2 FLUOROETHYL) 2,4 DIETHYL 3 (ETHYLSULFANYLCARBONYL) 6 PHENYLPYRIDINE 5 CARBOXYLATE; 5-(2-FLUOROETHYL) 2,4-DIETHYL-3-(ETHYLSULFANYLCARBONYL)-6-PHENYLPYRIDINE-5-CARBOXYLATE; DIAGNOSTIC AGENT; FLUORINE; NICOTINIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; MICHAELIS CONSTANT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SWINE; WILD TYPE; ANIMAL; CHEMISTRY; METABOLISM; RADIOCHEMISTRY;

ANIMALS; CARBOXYLESTERASE; DRUG STABILITY; FLUORINE RADIOISOTOPES; MALE; NICOTINIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOCHEMISTRY; RATS;

EID: 77952550249     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.01.001     Document Type: Article

References (14)

1. 3 adenosine receptor ligands: history and perspectives. Med Res Rev 2000, 20:103-128.
2. Fishman P., Bar-Yehuda S., Madi L., Cohn I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002, 13:437-443.
3. Madi L., Ochaion A., Rath-Wolfson L., Bar-Yehuda S., Erlanger A., Ohana G., et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 2004, 10:4472-4479.
4. Li A.H., Moro S., Forsyth N., Melman N., Ji X.D., Jacobson K.A. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 1999, 42:706-721.
5. 18F]FE@SUPPY). Radiochim. Acta 2008, 96:119-124.
6. 3 receptor. Nucl Med Biol 2008, 35:61-66.
7. 76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography. Nucl Med Biol 2009, 36:3-10.
8. Satoh T., Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998, 38:257-288.
9. 18F]FE@SUPPY:2). Radiochim Acta 2009, 97:753-758.
10. 18F]FE@SUPPY. The Open Nuclear Medicine Journal 2009, 1:15-23.
11. Azéma L., Lherbet C., Baudoin C., Blonski C. Cell permeation of a Trypanosoma brucei aldolase inhibitor: evaluation of different enzyme-labile phosphate protecting groups. Bioorg Med Chem Lett 2006, 16:3440-3443.
12. 18F]FE@SUPPY. Heterocycles 2008, 75:339-356.
13. 3 receptor PET-tracers: in the nuclear medicine's service 2008, Vdm Verlag, Wien.
14. Stoops J.K., Hamilton S.E., Zerner B. Carboxylesterases (EC 3.1.1). Acomparison of some kinetic properties of horse, sheep, chicken, pig and ox liver carboxylesterases. Can J Biochem 1975, 53:865-873.